Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Khushalani NI, et al. J Immunother Cancer. 2022 Nov;10(11):e005684. doi: 10.1136/jitc-2022-005684. J Immunother Cancer. 2022. PMID: 36450385 Free PMC article. Clinical Trial.
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
Ferguson R, Chat V, Morales L, Simpson D, Monson KR, Cohen E, Zusin S, Madonna G, Capone M, Simeone E, Pavlick A, Luke JJ, Gajewski TF, Osman I, Ascierto P, Weber J, Kirchhoff T. Ferguson R, et al. Among authors: monson kr. Eur J Cancer. 2023 Aug;189:112923. doi: 10.1016/j.ejca.2023.05.011. Epub 2023 May 18. Eur J Cancer. 2023. PMID: 37301715 Free PMC article.
Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes.
Ibrahim M, Illa-Bochaca I, Fa'ak F, Monson KR, Ferguson R, Lyu C, Vega-Saenz de Miera E, Johannet P, Chou M, Mastroianni J, Darvishian F, Kirchhoff T, Zhong J, Krogsgaard M, Osman I. Ibrahim M, et al. Among authors: monson kr. Cancers (Basel). 2023 Dec 19;16(1):18. doi: 10.3390/cancers16010018. Cancers (Basel). 2023. PMID: 38201446 Free PMC article.
Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in Melanoma.
Monson KR, Ferguson R, Handzlik JE, Xiong J, Dagayev S, Morales L, Chat V, Bunis A, Sreenivasaiah C, Dolfi S, Tenney DJ, Shao Y, Osman I, Weber JS, Kirchhoff T. Monson KR, et al. Clin Cancer Res. 2024 Oct 1;30(19):4412-4423. doi: 10.1158/1078-0432.CCR-24-0900. Clin Cancer Res. 2024. PMID: 39115425
Altered salivary microbiota associated with high-sugar beverage consumption.
Fan X, Monson KR, Peters BA, Whittington JM, Um CY, Oberstein PE, McCullough ML, Freedman ND, Huang WY, Ahn J, Hayes RB. Fan X, et al. Among authors: monson kr. Sci Rep. 2024 Jun 11;14(1):13386. doi: 10.1038/s41598-024-64324-w. Sci Rep. 2024. PMID: 38862651 Free PMC article.
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, Katabi N, Fury MG. Hyman DM, et al. Cancer Chemother Pharmacol. 2015 Apr;75(4):747-55. doi: 10.1007/s00280-015-2693-z. Epub 2015 Feb 12. Cancer Chemother Pharmacol. 2015. PMID: 25672916 Free PMC article. Clinical Trial.
162 results